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Abstract
Background: There is still an ongoing discussion on the prognostic value of cystatin C in assessment of kidney
function. Accordingly, the present study aimed to conduct a meta-analysis to provide evidence for the prognostic
value of this biomarker for acute kidney injury (AKI) in children.
Methods: An extensive search was performed in electronic databases of Medline, Embase, ISI Web of Science,
Cochrane library and Scopus until the end of 2015. Standardized mean difference (SMD) with a 95% of confidence
interval (95% CI) and the prognostic performance characteristics of cystatin C in prediction of AKI were assessed.
Analyses were stratified based on the sample in which the level of cystatin C was measured (serum vs. urine).
Results: A total of 24 articles were included in the meta-analysis [1948 children (1302 non-AKI children and 645 AKI
cases)]. Serum (SMD = 0.96; 95% CI: 0.68-1.24; p < 0.0001) and urine (SMD = 0.54; 95% CI:0.34-0.75; p < 0.0001) levels
of cystatin C were significantly higher in children with AKI. Overall area under the curve of serum cystatin C and
urine cystatin C in prediction of AKI were 0.83 (95% CI: 0.80-0.86) and 0.85 (95% CI: 0.81-0.88), respectively. The best
sensitivity (value = 0.85; 95% CI: 0.78-0.90) and specificity (value = 0.61; 95% CI: 0.48-0.73), were observed for the
serum concentration of this protein and in the cut-off points between 0.4-1.0 mg/L.
Conclusion: The findings of the present study showed that cystatin C has an acceptable prognostic value for
prediction of AKI in children. Since the serum level of cystatin C rises within the first 24 h of admission in patients
with AKI, this biomarker can be a suitable alternative for traditional diagnostic measures.
Keywords: Cystatin C, Acute kidney injury, Prognostic value
Background
Acute kidney injury (AKI) is considered as one of the
main public health issues all over the world. The precise
prevalence of AKI in children and adolescents is un-
known. However, evidences showed that the prevalence
of pediatric AKI is increasing [1–4]. This disease is a risk
factor for cardiovascular diseases, myocardial infarction
and heart failure. The main causes of mortality in chil-
dren with kidney failure are cardiovascular diseases and
infections [5, 6]. AKI in children pose a great burden on
the health care system and their families [7, 8]. However,
recent studies have shown that preventive strategies can
significantly decrease this burden [9]. Early detection
and treatment can also considerably lower the costs of
this health issue. Unfortunately, AKI are asymptomatic
and their signs and symptoms become evident only
when a great proportion of kidneys have lost their func-
tion [10]. Accordingly, all physicians in all specialties
should be aware of the importance of early diagnosis
and treatment of AKI in children.
Multiple diagnostic methods have been proposed for
detection of AKI in children but none can accurately
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predict the outcome [11, 12]. In the past decade various
studies have proposed measuring the serum level of
certain biomarkers as a new method for early diagnosis of
AKI [13–15], among which major attention has been
drawn to cystatin C [16] which has been shown to be use-
ful in diagnosing AKI and predicting its outcomes [17].
Cystatin C is a 13 kilo Dalton proteinase inhibitor
from the cystatin super family of cysteine protease inhib-
itors which plays and important role in intra-cellular
catabolism of proteins and peptides. Some studies have
shown that this biomarker is a better indicator of kidney
function compared to creatinine [16, 17], but still no
widespread recommendations exist for its use [18]. One
way to reach a general conclusion is conducting a
systematic review and meta-analysis [19–22]. In this re-
gard, Dharnidharka et al showed that cystatin C has a
far greater value in assessment of glomerular filtration
status compared to creatinine [16]. On the contrary,
Roos et al. carried out another systematic review in
2007, the results of which showed that the diagnostic
values of these two biomarkers are similar to each other
[17]. In another systematic review conducted by Zheng
et al. in 2011, the serum level of cystatin C was shown
to be a suitable hematologic biomarker in diagnosing
AKI while its urine concentration has a moderate diag-
nostic value for this purpose [23]. Feng et al. reviewed 6
articles and reported that an increase in cystatin C level
is associated with increased risk of mortality and the
need for dialysis in a 5-year follow up in patients with
AKI [24]. These four meta-analyses included articles
with adult sample populations, while recently a signifi-
cant growth has been observed in the number of studies
evaluating this matter in children, which highlight the
need for conducting a meta-analysis on data gathered
from children. Accordingly, the authors of the present
study aimed to conduct a systematic review and meta-
analysis to provide evidence on the prognostic value of
cystatin C in AKI in children.
Methods
Search strategy
This study was designed based on the Meta-analysis of
Observational Studies in Epidemiology statement [25].
The search strategy protocol and summarizing the
results is presented in our previous studies in details
[19–22, 26–36]. In summary, two independent reviewers
carried out an extensive search in in electronic databases
of Medline, ISI Web of Science, Embase, Cochrane
library and Scopus until the end of 2015. Keywords were
established using Mesh from the PubMed database,
Emtree from the Embase database and manual search in
the titles of similar articles. Search was based on the
words related to cystatin C and acute kidney injury.
Queries used in the databases of Medline and Embase
are presented in the Table 1.
In order to find further articles or non-indexed data,
hand-search in the reference lists of relevant studies was
done. Google search engine, Google scholar and
ProQuest were also manually searched.
Selection criteria
Both retrospective and prospective, cohort and cross-
sectional studies evaluating the prognostic value of
cystatin C in detection of AKI in children (age < 18 years
old) were included in the present study. Measuring the
level of cystatin C after the final diagnosis of AKI,
evaluating animals and using a reference test incompat-
ible with standard criteria were considered as the
exclusion criteria.
Data extraction and quality assessment
The results of the search in databases were pooled and
repetitive articles were removed using EndNote (version
X7, Thomson Reuters Company) software. Studies were
evaluated and controlled regarding their research meth-
odology and the summary of extracted resources were
assessed independently by two separate reviewers. The
Table 1 Queries used for the search in Medline and Embase databases
Database Query
Medline ("Cystatin C"[Mesh] OR "Cystatin C"[TIAB] OR "Post-gamma-Globulin"[TIAB] OR "Post gamma Globulin"[TIAB] OR "Neuroendocrine Basic
Polypeptide"[TIAB] OR "Basic Polypeptide, Neuroendocrine"[TIAB] OR "Cystatin 3"[TIAB] OR "gamma-Trace"[TIAB] OR "gamma Trace"[TIAB])
AND ("Acute Kidney Injury"[Mesh] OR "Acute Kidney Injuries"[TIAB] OR "Kidney Injuries, Acute"[TIAB] OR "Kidney Injury, Acute"[TIAB] OR
"Acute Renal Injury"[TIAB] OR "Acute Renal Injuries"[TIAB] OR "Renal Injuries, Acute"[TIAB] OR "Renal Injury, Acute"[TIAB] OR "Renal
Insufficiency, Acute"[TIAB] OR "Acute Renal Insufficiencies"[TIAB] OR "Renal Insufficiencies, Acute"[TIAB] OR "Acute Renal Insufficiency"[TIAB]
OR "Kidney Insufficiency, Acute"[TIAB] OR "Acute Kidney Insufficiencies"[TIAB] OR "Kidney Insufficiencies, Acute"[TIAB] OR "Acute Kidney
Insufficiency"[TIAB] OR "Kidney Failure, Acute"[TIAB] OR "Acute Kidney Failures"[TIAB] OR "Kidney Failures, Acute"[TIAB] OR "Acute Renal
Failure"[TIAB] OR "Acute Renal Failures"[TIAB] OR "Renal Failures, Acute"[TIAB] OR "Renal Failure, Acute"[TIAB] OR "Acute Kidney
Failure"[TIAB] OR "Acute Kidney Tubule Necrosis"[TIAB])
Embase 'cystatin c'/exp OR 'post-gamma-globulin'/exp OR 'post gamma globulin'/exp OR 'neuroendocrine basic polypeptide'/exp OR 'basic
polypeptide, neuroendocrine' OR 'cystatin 3'/exp OR 'gamma-trace'/exp OR 'gamma trace'/exp AND ('acute kidney injuries' OR 'kidney
injuries, acute' OR 'kidney injury, acute' OR 'acute renal injury'/exp OR 'acute renal injuries' OR 'renal injuries, acute' OR 'renal injury, acute'
OR 'renal insufficiency, acute'/exp OR 'acute renal insufficiencies' OR 'renal insufficiencies, acute' OR 'acute renal insufficiency'/exp OR
'kidney insufficiency, acute'/exp OR 'acute kidney insufficiencies' OR 'kidney insufficiencies, acute' OR 'acute kidney insufficiency'/exp OR
'kidney failure, acute'/exp OR 'acute kidney failures' OR 'kidney failures, acute' OR 'acute renal failure'/exp OR 'acute renal failures' OR 'renal
failures, acute' OR 'renal failure, acute' OR 'acute kidney failure'/exp OR 'acute kidney tubule necrosis'/exp)
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reason for dismissal of any articles was recorded. In case
of disagreement between the two reviewers, a third re-
viewer studied the article and solved the disagreement
through discussion (inter-rate reliability = 0.91). Results
of the search were recorded in a checklist according to
the guidelines designed by PRISMA statement [37].
Extracted data included information about the study set-
ting, patients’ characteristics, definition of AKI, evalu-
ation time, sample type (urine, serum), number of
evaluated samples, outcome of the patients (progression
to AKI or non-AKI) and possible bias. In cases of repeti-
tive results, the study including the larger sample popu-
lation was included. If data were not extractable from
the article, the corresponding author was contacted and
asked to provide the information. If data were presented
as charts, the extraction method proposed by Sistrom
and Mergo was utilized [38]. In cases where only sensi-
tivity and specificity were reported, reliable online soft-
ware was used for calculation of true positive (TP), true
negative (TN), false positive (FP) and false negative (FN).
Quality status of the articles was assessed using the
14-item Quality Assessment of Diagnostic Accuracy
Studies (QUADAS2) tool [39]. Only studies with a qual-
ity rate of good or fair were included in the sensitivity
analysis.
Articles in which an appropriate reference test was not
used for defining acute kidney injury were considered as
having a poor quality and were excluded from the study.
Good articles were the ones in which all the seven
QUADAS-2 items were found to be acceptable (have
low risk of bias). Even if an article had used an appropri-
ate reference test but at least one of the other
QUADAS-2 items has high risk of bias or was unclear, it
was considered as having a fair quality.
Statistical analysis
All the results of the studies were summarized into
means and standard deviations, TP, FP, TN and FN.
Heterogeneity between the studies was evaluated using
Chi-squared and I2 tests and a p value of less than 0.1
was considered as statistically significant (indicative of
heterogeneity) [40]. If the studies were homogenous,
fixed effect model was used. In case of a positive hetero-
geneity, subgroup analysis was performed to identify the
sources of heterogeneity. If the source of heterogeneity
was not identified, random effect model was used. Even-
tually, all the results were pooled and an overall effect
size was presented.
Analyses were carried out in two steps. In the first step
the mean level of cystatin C was compared between the
two groups AKI and non-AKI by calculating standard-
ized mean difference (SMD) with a confidence interval
of 95% (95% CI) based on Hedge g. in this step,
publication bias was also assessed through drawing fun-
nel plots using Egger’s and Begg’s tests [41].
In the second step, TP, FP, TN and FN cases in AKI
and non-AKI patients were recorded separately for each
study. These values were used for calculation of area
under the curve (AUC), sensitivity, specificity, positive
likelihood ratio and negative likelihood ratio with a 95%
confidence interval (95% CI). Mixed-effects binary
regression model, a type of random effect model was
used in this section. This strategy was selected due to
the significant heterogeneity between the articles.
Subgroup analysis was performed to identify the sources
of heterogeneity using a bivariate mixed-effects binary
regression model. Deeks’ funnel plot asymmetry test was
used for evaluation of publication bias.
Analyses were stratified based on the samples in which
cystatin C level was measured (serum and urine).
STATA version 11.0 (Stata Corporation, College Station,
TX) was used for data analysis.
Results
Characteristics of included studies
After the initial screening of the search results, full texts
of 115 articles were studied and a total of 24 articles
were included in the meta-analysis (Fig. 1) [9, 42–64].
These articles included data from 1948 children (1302
non-AKI children and 645 AKI cases). The mean age of
these children was 3.1 years old and 54.1% were boys.
The most common settings were children hospitalized
in the intensive care unit (ICU) in 10 studies [44, 45, 49,
52, 55, 56, 58, 59, 61, 63] and post cardiac surgery in 8
surveys [42, 50, 51, 53, 54, 57, 60, 64]. Eighteen articles
measure the serum level of cystatin C [42, 43, 45, 46,
48–52, 54, 57–61, 63, 64] and five assessed the urine
concentration of this protein [9, 44, 53, 55, 56]. Two
studies measured the level of cystatin C in both urine
and serum samples [47, 62].
AKI was defined as at least a 20% decrease in eCCl
from baseline in seven studies, as 50% increase or rise in
SCr of at least 0.3 mg/dL in nine studies, as the doubling
of SCr from baseline in two surveys and as a GFR <
80 mL/min/1.73 m2 in four studies. The other four sur-
veys had used other standard definitions for AKI. It
should be mentioned that two studies had used more
than one definition for classifying children with AKI.
Table 2 presents the characteristics of these studies.
Heterogeneity and publication bias
Analyses are presented in two separate sections evaluat-
ing the correlation between the serum level of cystatin C
with occurrence of AKI and that of the urine concentra-
tion of this protein. In assessing the relation between
serum level of cystatin C with AKI, a significant hetero-
geneity was observed between the studies (I2 = 91.2%;
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p < 0.001) while minor heterogeneity was found in the
second part of our analyses evaluating the urine concen-
tration of cystatin C (I2 = 49.1%; p = 0.04). In overall
analysis no publication bias was found in assessment of
the relation between serum level (coefficient = 0.9; 95%
CI:-1.4-3.2; p = 0.44) and urine level (coefficient = 1.1; 95%
CI:-3.9-3.3; p = 0.09) of cystatin C with AKI.
Meta-analysis
Relation between the level of cystatin C with occurrence of
AKI
In 22 studies the mean or median of cystatin C level was
compared between the two groups of AKI and non-AKI
children [9, 42, 44–55, 57–64].
Analyses showed that the serum level of cystatin C
was significantly higher in AKI patients compared to
non-AKI subjects (SMD = 0.96; 95% CI: 0.68-1.24; p <
0.0001). Serum cystatin C level measured on arrival
(SMD = 0.98; 95% CI:0.39-1.57 l p < 0.0001), after 6 h
(SMD = 0.72; 95% CI:0.09-1.36; p < 0.0001), after 12 h
(SMD = 1.29; 95% CI:0.54-2.04; p < 0.0001) and after
24 h (SMD = 0.99; 95% CI:0.55-1.43; p < 0.0001) were all
significantly higher in AKI patients (Fig. 2 and Table 3).
It seems that the setting of the study affects the serum
level of cystatin C in patients. As presented in Table 3
the serum level of cystatin C in children with AKI
admitted to the pediatric intensive care unit (SMD =
1.50; 95% CI: 1.02-1.99; p < 0.001) and the ones who
developed AKI following cardiac surgery (SMD = 0.71;
95% CI: 0.41-1.02; p < 0.001) was significantly higher
than non-AKI children while in other settings (including
sepsis, cancer, Low Birth Weight Infants, Contrast in-
duced nephropathy, Contrast induced nephropathy and
Asphyxia) no significant difference was observed
between AKI and non-AKI children (SMD = 1.09; 95%
CI: -1.15-3.33; p = 0.34). The temperature at which
serum was stored before conducting protein assays was
another factor affecting the prognostic value of serum
cystatin C level. The results showed a significant differ-
ence in the levels of cystatin C between AKI and non--
AKI children when their serum were stored at the
temperatures of -70 °C (SMD = 1.06; 95% CI: 0.66-1.46;
p < 0.001) and -80 °C (SMD = 0.97; 95% CI: 0.57-1.41; p
< 0.001) but such association was not observed in
patients whose sera were stored at -20 °C (SMD = 0.82;
95% CI: -0.19-1.83; p = 0.11).
Timing of AKI definition (p = 0.44), AKI definition cri-
teria (p = 0.79), and sample size of study (p = 0.23) had
no significant effects on the difference between AKI and
non-AKI children regarding their reported serum levels
of cystatin C in the serum.
The urine level of this protein was also found to be
higher in children with AKI (SMD = 0.54; 95% CI:
0.34-0.75; p < 0.0001). Cystatin C levels on arrival
(SMD = 0.70; 95% CI: 0.37-1.03; p < 0.0001) and after
12 h (SMD = 0.38; 95% CI: 0.19-0.58; p < 0.0001) were
significantly higher in AKI patients but the differences
in its levels between AKI and non AKI subjects after
24 h (SMD = 0.53; 95% CI:-0.61-1.67; p = 0.36) were
not statistically significant (Fig. 3 and Table 3).
Fig. 1 Flowchart of present systematic review and meta-analysis
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In addition, timing of AKI definition (p = 0.11), AKI
definition criteria (p = 0.11), sample size of study (p =
0.34), storage degree (p = 0.26) and setting of study
(p = 0.21) did not affect the difference in urine cysta-
tin C levels between AKI and non-AKI children.
As can be seen, a significant heterogeneity was found
between the studies. Subgroup analysis and meta-
regression was carried out in order to find the sources of
heterogeneity. This analysis revealed that the most
important source of heterogeneity in assessment of
serum cystatin C level were the setting of the studies
and storage degree of serum. Results of this section are
presented in Table 4.
Since only 6 studies were included in the analyses on
urine cystatin C level, meta-regression could not be
performed due to statistical limitations.
Diagnostic performance characteristics of cystatin C in
AKI
Table 5 presents the sensitivity, specificity and diagnostic
likelihood ratio of the level of cystatin C protein in
detection of AKI in different cut off points. Overall AUC
of serum cystatin C in prediction of AKI was 0.83 (95%
CI: 0.80-0.86) (Fig. 4-a). The area under the curve in
cut-off points of 0.4-1.0 mg/L and 1.01-2.5 mg/L were
0.83 (95% CI: 0.80-0.86) and 0.85 (95% CI: 0.82-0.88),
respectively. Overall area under the curve of urine
cystatin C in prediction of AKI was 0.85 (95% CI:
0.81-0.88) (Fig. 4-b). Since only four studies were
included in urine level analysis, subgroup analysis was
not performed. There was no significant difference
between AUC of serum and urine levels of cystatin C
in prediction of AKI (p = 0.25)
Fig. 2 Value of serum cystatin C in prediction of acute kidney injury by time assessment. CI, confidence interval. Effect size were assessed by calculating
standardized mean difference
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Table 3 Primary subgroup analyses of serum and urine level of cystatin C in patients with acute kidney injury
Characteristics P for publication bias Model P for heterogeneity (I
2) SMD (95% CI) P for effect size
a) Serum level
Timing of cystain C assessment
Overall 0.44 REM <0.001 (89.9%) 0.96 (0.68-1.24) <0.001
Baseline 0.37 REM <0.001 (91.1%) 0.98 (0.39-1.57) <0.001
1-6 h 0.90 REM <0.001 (91.2%) 0.72 (0.09-1.36) <0.001
7-12 h >0.99 REM <0.001 (01.1%) 1.29 (0.54-2.04) <0.001
13-24 h 0.66 REM <0.001 (83.4%) 0.99 (0.55-1.43) <0.001
Overall Significant difference among subgroups 0.62
Timing of AKI definition
Within 24 h 0.07 REM <0.001 (94.6%) 0.88 (-0.40-2.17) 0.18
Within 48 h 0.60 REM <0.001 (93.2%) 1.05 (0.62-1.15) <0.001
Within 72 h 0.57 REM <0.001 (76.0%) 0.74 (0.28-1.10) 0.002
More than 72 h 0.17 REM <0.001 (86.2%) 1.58 (0.77-2.38) <0.001
Overall Significant difference among subgroups 0.44
AKI definition
Decrease in eCCl by at least 20% from baseline 0.06 REM <0.001 (94.5%) 1.07 (0.29-1.84) 0.007
50% increase or rise SCr of at least 0.3 mg/dL 0.58 REM <0.001 (89.0%) 0.72 (0.37-1.08) <0.001
GFR < 80 mL/min/1.73 m2 0.36 REM <0.001 (78.8%) 1.25 (0.83-1.67) <0.001
Doubling of SCr from baseline 0.34 FEM 0.61 (0.0%) 0.07 (-0.29-0.44) 0.69
Other 0.30 REM <0.001 (92.4%) 2.61 (0.24-5.45) 0.07
Overall Significant difference among subgroups 0.79
Setting
PICU 0.69 REM <0.001 (82.1%) 1.50 (1.02-1.99) <0.001
Cardiac surgery 0.60 REM <0.001 (90.5%) 0.71 (0.41-1.02) <0.001
Other 0.03 REM <0.001 (91.0%) 1.09 (-1.15-3.33) 0.34
Overall Significant difference among subgroups 0.02
Sample size
≤30 0.04 REM <0.001 (78.0%) 1.90 (0.98-2.82) <0.001
>30 0.91 REM <0.001 (92.3%) 0.80 (0.50-1.10) <0.001
Overall Significant difference among subgroups 0.23
Storage degree
-20 0.01 REM <0.001 (90.0%) 0.82 (-0.19-1.83) 0.11
-70 0.54 REM <0.001 (91.7%) 1.06 (0.66-1.46) <0.001
-80 0.60 REM <0.001 (90.3%) 0.97 (0.57-1.41) <0.001
Overall Significant difference among subgroups 0.005
b) Urine level
Timing of cystain C assessment
Overall 0.09 REM 0.04 (49.1%) 0.54 (0.34-0.75) <0.001
Baseline 0.07 REM 0.01 (63.3%) 0.70 (0.37-1.03) <0.001
1-12 h 0.03 FEM 0.93 (0.0%) 0.38 (0.19-0.58) <0.001
13-24 h 0.11 REM >0.99 (0.0%) 0.55 (-0.61-1.67) 0.36
Overall Significant difference among subgroups 0.83
AKI definition
Decrease in eCCl by at least 20% from baseline 0.32 FEM 0.82 (0.0%) 1.84 (0.78-2.89) 0.007
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The best sensitivity and specificity were observed
for the serum concentration of cystatin C and in the
cut-off points between 0.4-1.0 mg/L, calculated to be
0.85 (95% CI:0.78-0.90) and 0.61 (95% CI:0.48-0.73),
respectively.
Discussion
The present study aimed to gather information on the
predictive value of cystatin C for AKI in children. The
results for both urine and serum concentrations of this
biomarker showed that cystatin C has an acceptable
Table 3 Primary subgroup analyses of serum and urine level of cystatin C in patients with acute kidney injury (Continued)
50% increase or rise SCr of at least 0.3 mg/dL 0.27 FEM 0.06 (52.2%) 0.56 (0.31-0.82) <0.001
Doubling of SCr from baseline 0.32 REM 0.04 (49.1%) 0.38 (0.16-0.59) 0.69
Overall Significant difference among subgroups 0.11
Timing of AKI definition
Within 24 h 0.74 FEM 0.99 (0.0%) 0.37 (0.23-0.51) 0.18
Within 48 h 0.18 FEM 0.14 (41.7%) 1.04 (0.55-1.52) <0.001
Overall Significant difference among subgroups 0.11
Setting
PICU 0.74 FEM 0.23 (31.1%) 0.91 (0.44-0.74) <0.001
Cardiac surgery 0.38 FEM 0.99 (0.0%) 0.37 (0.23-0.51) <0.001
Other 0.04 FEM 0.12 (52.2%) 1.20 (0.18-2.23) 0.02
Overall Significant difference among subgroups 0.21
Sample size
≤30 0.10 FEM 0.20 (34.7%) 0.97 (0.24-1.69) 0.009
>30 0.04 REM 0.05 (55.2%) 0.49 (0.30-0.69) <0.001
Overall Significant difference among subgroups 0.34
Storage degree
-20 0.32 REM 0.08 (68.4%) 0.98 (-0.06-2.02) 0.11
-80 0.05 FEM 0.11 (40.7%) 0.48 (0.30-0.66) <0.001
Overall Significant difference among subgroups 0.26
AKI acute kidney injury, CI confidence interval, FEM fixed effect model, REM random effect model, SMD standardized mean difference, Bold values are significant.
Significance among subgroups were calculated based on univariate meta-regression analysis
Fig. 3 Value of urine cystatin C in prediction of acute kidney injury by time assessment. CI, confidence interval. Effect size were assessed by
calculating standardized mean difference
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prognostic value for prediction of AKI in children. We
included studies that had evaluated the serum or urine
level of cystatin C in the first 24 h after admission or
surgery of the patients. In most of these studies AKI had
been diagnosed by conventional biomarkers such as
serum creatinine level in the second, third or fourth day
(24-96 h) post-admission or surgery. So it seems that
cystatin C rises earlier than serum creatinine in response
to AKI and can be a potential substitute for creatinine
concentration.
It seems that the serum level of cystatin C has a higher
predictive value for AKI compared to its urine concen-
tration. However, the number of studies with cystatin C
urine concentration assessment was limited [9, 44, 47,
53, 55, 62], which caused the p value of publication bias
evaluation to be borderline (p = 0.09). In agreement with
these findings, two other meta-analyses had shown the
superiority of serum cystatin C levels to its urine
concentrations for predicting the progression of AKI
[16, 23]. Following an AKI the serum level of this pro-
tein rises earlier than its urine level and in order for the
cystatin C urine concentration to rise, tubular injury
should occur [65], while in a considerable number of
these patients, tubular injury does not occur in the first
stages of AKI. In addition, a substantial portion of the
cystatin C that is filtered at the glomerulus is metabo-
lized by the kidney [66]. Hence, it is anticipated that the
urine concentration of cystatin C rises later than its
serum levels in response to AKI.
Two factors should be evaluated when the prognostic
value of a biomarker in prediction of AKI is being
assessed. The first one is the time of assessment and the
second is the cut-off point. A suitable biomarker should
be able to diagnose a condition in the shortest amount
of time with a high accuracy [31, 67]. In available litera-
ture on this subject, the level of cystatin C was assessed
at different times (from arrival to 72 h after the surgery
or admission); however, since time plays an important
role in prognosis of AKI patients we decided to include
data in which the level of cystatin C was measured in
the first 24 h after arrival of the patient (or after
surgery). The results showed that the relation between
the urine or serum level of cystatin C with occurrence of
AKI is not affected by the time in which the concentra-
tion is measured in the first 24 h. So, it can be
concluded that assessing the level of cystatin C in the
first 24 h can predict occurrence of AKI in the following
days and its prognostic value does not significantly differ
whether its concentration is measured on arrival or after
24 h. In this regard, it is suggested that a serum sample
should be drawn on arrival for measuring the level of
cystatin C in order to assess the risk of AKI
development.
Moreover, it should be noted that in the majority of
included studies in this meta-analysis, AKI was diag-
nosed based on the rise in serum creatinine level
between 24 to 96 h post-admission or surgery while the
findings of this survey showed that serum cystatin C
levels measured in the first 24 h, can predict develop-
ment of AKI in the next few days. So it seems that
cystatin C levels respond to AKI earlier than the conven-
tional biomarkers such as creatinine and urine output,
one of the strengths of this biomarker compared to
others. To confirm this hypothesis, direct comparison
between cystatin C and creatinine levels could not be
performed due to the limited number of studies which
had included this direct comparison in their analyses.
Nevertheless, AKI was defined based on serum creatin-
ine levels in the included studies and so an indirect
Table 4 Multivariate meta-regression analysis for assessment of
source of heterogeneity in serum level of cystatin C
Variable Odds ratio 95% CI P
Timing of Cystatin C
Baseline Ref. Ref. —
1-6 h 2.34 0.86-6.34 0.09
7-12 h 1.92 0.60-6.15 0.26
13-24 h 1.52 0.65-3.56 0.32
Timing of AKI definition
Within 24 h Ref. Ref. —
Within 48 h 0.44 0.07-3.00 0.39
Within 72 h 0.16 0.02-1.46 0.10
More than 72 h 0.58 0.05-6.8 0.65
AKI definition
Other Ref. Ref. —
Decrease in eCCl by at least 20% from
baseline
0.08 0.002-2.32 0.13
50% increase or rise SCr of at least
0.3 mg/dL
0.06 0.004-1.07 0.09
GFR < 80 mL/min/1.73 m2 0.07 0003-1.97 0.12
Doubling of SCr from baseline 0.11 0.01-1.3 0.08
Setting
Other Ref. Ref. —
Cardiac surgery 2.52 0.45-14.17 0.24
PICU admitted 5.45 1.23-24.10 0.03
Sample size
≤30 Ref. Ref. —
>30 0.43 0.10-1.80 0.23
Storage degree
-20 Ref. Ref. —
-70 10.03 1.61-62.27 0.02
-80 11.69 1.13-121.08 0.04
AKI acute kidney injury, CI confidence interval, PICU pediatric intensive care
unit, Bold values are significant
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comparison has already been conducted between the
two biomarkers.
The cut off points also differed between included
studies (ranging from 0.4 mg/L to 2.5 mg/L) so we
categorized these articles into two groups of a cut-off
point less than 1.0 mg/L and a cut-off point off higher
than 1.0 mg/L (serum level). The cut-off level of 1 mg/L
was selected based on the previous studies showing that
the normal serum level of this biomarker in children
aged 1 to 17 is always less than this level [68].
The extensive search in electronic databases and using
hand-search to yield maximum relevant articles add to
the strength of the present study. Another strength of
this survey was the subgroup analysis performed based
on two important factors of measuring time and cut-off
point. The significant heterogeneity observed between
the included studies was one of the weaknesses in this
survey, the source of which was identified to be the
setting of these studies. Moreover, in assessing the diag-
nostic value of cystatin C urine concentration, only six
Table 5 Diagnostic performance characteristics of cystatin C in detection of acute kidney injury
Characteristics TP FP FN TN P for publication bias Model P for heterogeneity (I
2) Effect size (95% CI)
a) Serum level 543 445 206 1102
Overall area under the curve 0.08 REM <0.001 (80.0) 0.83 (0.80-0.86)
0.4-1 mg/L 314 361 53 386
Sensitivity 0.29 REM <0.001 (77.6) 0.85 (0.78-0.90)
Specificity 0.29 REM <0.001 (94.6) 0.61 (0.48-0.73)
Positive likelihood ratio 0.29 REM <0.001 (92.8) 2.18 (1.66-2.88)
Negative likelihood ratio 0.29 REM 0.01 (60.3) 0.24 (0.18-0.34)
1.01-2.5 mg/L 229 84 153 716
Sensitivity 0.01 REM <0.001 (87.1) 0.65 (0.49-0.77)
Specificity 0.01 REM <0.001 (87.8) 0.88 (0.79-0.94)
Positive likelihood ratio 0.01 REM <0.001 (64.5) 5.56 (3.62-8.53)
Negative likelihood ratio 0.01 REM <0.001 (85.5) 0.40 (0.28-0.56)
b) Urine level 93 37 128 295
Overall area under the curve 0.07 REM <0.001 (83.3) 0.85 (0.81-0.88)
Sensitivity 0.07 REM <0.001 (83.3) 0.47 (0.29-0.66)
Specificity 0.07 REM 0.09 (54.3) 0.89 (0.83-0.93)
Positive likelihood ratio 0.07 FEM 0.24 (0.0) 4.24 (2.93-6.13)
Negative likelihood ratio 0.07 REM 0.04 (63.2) 0.60 (0.43-0.83)
AKI acute kidney injury, CI confidence interval, FEM fixed effect model, REM random effect model, TP true positive, TN true negative, FP false positive, FN
false negative
Fig. 4 Summary receiver operative curves (SROC) for cystatin C in detection of acute kidney injury. a Serum; b Urine. AUC: Area under the curve;
SENS: Sensitivity; SPEC: Specificity
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studies were included which makes the yielded results
susceptible to publication bias. It should also be
mentioned that all the included studies were observa-
tional surveys which increases the possibility of selection
bias in these studies.
Finally, it should be mentioned that the definition of
AKI differed between the studies which might have
affected the results of the survey. On the other hand,
AKI had been diagnosed at different times (between 24
to 720 h) which made interpretation of the findings
quite difficult and their generalization doubtful. How-
ever, subgroup analysis and meta-regression showed that
the differences in definition and timing of AKI do not
affect the prognostic value of cystatin C in predicting
development of AKI.
Conclusion
The present meta-analysis is the first to assess the prog-
nostic value of cystatin C in detection of AKI in
pediatric population. The findings of this study showed
that cystatin C has an acceptable prognostic value for
prediction of AKI in children, with its serum concentra-
tion diagnostic value being higher than that of its urine
level. So, measuring cystatin C serum level in the first
24 h and considering a cut-off point between 0.4-
1.0 mg/L provides the highest value in predicting AKI.
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